Search Result

Results for "

type-II diabetes

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) AMPK (1) Amylases (2) Amylin Receptor (1) Apoptosis (2) Drug Metabolite (1) Endogenous Metabolite (3) Free Fatty Acid Receptor (6) Fungal (1) GLP Receptor (1) Glucosidase (4) Lipoxygenase (1) MAGL (1) Mitochondrial Metabolism (1) Phosphatase (1) Phosphodiesterase (PDE) (1) PPAR (4) Reactive Oxygen Species (1) SGLT (1) Stearoyl-CoA Desaturase (SCD) (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Endocrinology (1) Infection (2) Inflammation/Immunology (3) Metabolic Disease (31) Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Targets Recommended: Photosystem II PCSK9 CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-110178

WWL123	MAGL	Inflammation/Immunology
WWL123, a carbamate-based compound, is a potent and selective ABHD6 inhibitor. WWL123 can be used for research of inflammation, metabolic disorders (obesity and type II diabetes mellitus) and epilepsy .

HY-154972

α-Amylase/α-Glucosidase-IN-3	Glucosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an α-Amylase/α-Glucosidase dual inhibitor, with IC₅₀s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus .

HY-161429

Antidiabetic agent 5	Amylases Glucosidase	Metabolic Disease
Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and α-amylase with IC₅₀ values of 3.91, 8.89 µM, respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes .

HY-120223

BMS-196085	Adrenergic Receptor	Metabolic Disease
BMS-196085 is an orally active, potent and selective full agonist against human β₃ adrenergic receptor with a K_i value of 21 nM. BMS-196085 also has partial agonist activity at the β₁ receptor. BMS-196085 is promising for research of obesity and type-II diabetes .

HY-114632

Oxeglitazar	Others	Metabolic Disease
Oxeglitazar is an orally active compound that can be used for the research of type II diabetes .

HY-141653

MK-8666 tromethamine	Free Fatty Acid Receptor	Metabolic Disease
MK-8666 (tromethamine) is a GPR40 agonist. MK-8666 (tromethamine) can be used in the research of type II diabetes .

HY-120886

GW 2433	PPAR	Metabolic Disease
GW 2433 is a dual PPARα and PPARδ agonist. GW 2433 has the potential for the study of type II diabetes and dyslipidemia .

HY-16619

AM-5262	Free Fatty Acid Receptor	Metabolic Disease
AM-5262 is a GPR40 full agonist with an EC₅₀ value of 0.081 μM. AM-5262 can be used for the research of type II diabetes .

HY-P10312

SPN009	GLP Receptor	Metabolic Disease
SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC₅₀ of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .

HY-162042

AMPK activator 14	AMPK	Metabolic Disease
AMPK activator 14 (compound 32) is an orally active AMPK activator. AMPK activator 14 decreases fasted glucose and insulin levels in a db/db mouse model of Type II diabetes .

HY-120160

Darglitazone CP-86325	PPAR	Neurological Disease Metabolic Disease
Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

HY-135335

3'-Hydroxy Repaglinide	Drug Metabolite	Metabolic Disease
3'-Hydroxy Repaglinide is a main CYP2C8 metabolite of Repaglinide. Repaglinide is a carbamoylmethyl benzoic acid (CMBA) derivative, which recently has become available for the treatment of type II diabetes .

HY-13525

CP-91149 4 Publications Verification	Others	Metabolic Disease Cancer
CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study .

HY-120160A

Darglitazone Sodium CP 86325 Sodium	PPAR	Neurological Disease Metabolic Disease
Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

HY-147964

α-Glucosidase-IN-9	Glucosidase	Metabolic Disease
α-Glucosidase-IN-9 (compound 7) is a potent α-glucosidase inhibitor, with an IC₅₀ of 55.6 μM. α-Glucosidase-IN-9 can be used for type II diabetes research .

HY-147965

α-Glucosidase-IN-10	Glucosidase	Metabolic Disease
α-Glucosidase-IN-10 (compound 13) is a potent α-glucosidase inhibitor, with an IC₅₀ of 92.7 μM. α-Glucosidase-IN-10 can be used for type II diabetes research .

HY-14728

Aleglitazar R1439; RO0728804	PPAR	Metabolic Disease
Aleglitazar (R1439) is a potent dual PPARα/γ agonist, with IC₅₀s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes .

HY-109500

Masoprocol meso-Nordihydroguaiaretic acid; meso-NDGA	Lipoxygenase	Metabolic Disease
Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .

HY-114520

TT01001	Mitochondrial Metabolism Apoptosis Reactive Oxygen Species	Neurological Disease Metabolic Disease
TT01001 is a potent and orally active mitoNEET ligand. TT01001 reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 improves type II diabetes without causing weight gain .

HY-160628

GPR120 Agonist 4	Free Fatty Acid Receptor	Metabolic Disease
GPR120 Agonist 4 (example 1) is a GPR120 agonist，with the EC₅₀ values of 1 μM and 0.35 μM for β-arrestin A and Calcium A. GPR120 Agonist 4 can be used for the research of type II diabetes mellitus .

HY-139077

SCD1 inhibitor-3	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease Cancer
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer .

HY-108196

PTP1B-IN-15	Phosphatase	Endocrinology
PTP1B-IN-15 is a potent and selective inhibitor of protein tyrosine phosphatase 1B (PTP1B). PTP1B-IN-15 has the potential for the research of type II diabetes and obesity .

HY-W011303

Phytosphingosine 1 Publications Verification 4-Hydroxysphinganine	Apoptosis Endogenous Metabolite Fungal Free Fatty Acid Receptor	Infection Metabolic Disease Inflammation/Immunology Cancer
Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC₅₀ value of 33.4 μM and can be used in the study of type II diabetes .

HY-N9153A

Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether	Others	Metabolic Disease
Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether is a DGAT1 inhibitor with an IC₅₀ of 92.7 μM and can be extracted from Eleutherococcus senticosus. Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether can be utilized in research related to type II diabetes and obesity .

HY-112603

AP5	Free Fatty Acid Receptor	Metabolic Disease
AP5 is a potent, orlly active, and selective GPR40 receptor agonist with a positive allosteric modulation of endogenous ligand (AgoPAM). AP5 demonstrates rat and human inositol monophosphate (IP1) EC₅₀ values of 0.49 nM and 0.8 nM against the GPR40 receptor, respectively. AP5 has the potential for type II diabetes research .

HY-42680

D-Tagatose D-(-)-Tagatose	Endogenous Metabolite	Metabolic Disease Cancer
D-Tagatose (D-(-)-Tagatose) is a rare monosaccharide found in nature with prebiotic characteristics. D-Tagatose is as a substitute for sucrose and a low-calorie sweetener in foodstuffs such as gum, fruit juice, and beverages. D-Tagatose is also a potential antidiabetic agent for the research of type II diabetes and a prebiotic to help elevate beneficial bacteria in the colon, prevent colon cancer, and lower cholesterol .

HY-P2501

Amylin (8-37), human	Amylin Receptor	Metabolic Disease
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .

HY-112603A

AP5 sodium	Free Fatty Acid Receptor	Metabolic Disease
AP5 sodium is a potent, orall active, and selective GPR40 receptor agonist with a positive allosteric modulation of endogenous ligand (AgoPAM). AP5 sodium demonstrates rat and human inositol monophosphate (IP1) EC₅₀ values of 0.49 nM and 0.8 nM against the GPR40 receptor, respectively. AP5 sodium has the potential for type II diabetes research .

HY-14810

Atigliflozin AVE-2268	SGLT	Metabolic Disease
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC₅₀s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .

HY-153530

LI-2242	Others	Neurological Disease Metabolic Disease
LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC₅₀ values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders .

HY-W011303A

(Rac)-Phytosphingosine (Rac)-4-Hydroxysphinganine	Others	Others
(Rac)-Phytosphingosine ((Rac)-4-Hydroxysphinganine) is the racemate of Phytosphingosine (HY-W011303). Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC₅₀ value of 33.4 μM and can be used in the study of type II diabetes .

HY-42680R

D-Tagatose (Standard)	Endogenous Metabolite	Metabolic Disease Cancer
D-Tagatose (Standard) is the analytical standard of D-Tagatose. This product is intended for research and analytical applications. D-Tagatose (D-(-)-Tagatose) is a rare monosaccharide found in nature with prebiotic characteristics. D-Tagatose is as a substitute for sucrose and a low-calorie sweetener in foodstuffs such as gum, fruit juice, and beverages. D-Tagatose is also a potential antidiabetic agent for the research of type II diabetes and a prebiotic to help elevate beneficial bacteria in the colon, prevent colon cancer, and lower cholesterol .

HY-153335

Enpp-1-IN-16	Phosphodiesterase (PDE)	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library	776 compounds
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 776 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Anti-diabetic Compound Library

776 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 776 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Target	Research Area

HY-P10312

SPN009	GLP Receptor	Metabolic Disease
SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC₅₀ of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .

HY-P4767

Amylin (1-13) (human)	Peptides	Metabolic Disease
Amylin (1-13) (human) is a fragment and a residues within amyloid cores of Amylin (human IAPP). Amylin is a glucose-regulating hormone, deposits as amyloid fibrils in condition of type II diabetes (T2D). Amylin (1-13) (human) has no effect on firbl formation, as it cannot form fibrils by itself .

HY-P2501

Amylin (8-37), human	Amylin Receptor	Metabolic Disease
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .

Masoprocol meso-Nordihydroguaiaretic acid; meso-NDGA	other families Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	Lipoxygenase
Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .

Phytosphingosine 1 Publications Verification 4-Hydroxysphinganine	Infection Structural Classification Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Apoptosis Endogenous Metabolite Fungal Free Fatty Acid Receptor
Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC₅₀ value of 33.4 μM and can be used in the study of type II diabetes .

D-Tagatose D-(-)-Tagatose	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Sweeteners Saccharides Monosaccharides Food Research	Endogenous Metabolite
D-Tagatose (D-(-)-Tagatose) is a rare monosaccharide found in nature with prebiotic characteristics. D-Tagatose is as a substitute for sucrose and a low-calorie sweetener in foodstuffs such as gum, fruit juice, and beverages. D-Tagatose is also a potential antidiabetic agent for the research of type II diabetes and a prebiotic to help elevate beneficial bacteria in the colon, prevent colon cancer, and lower cholesterol .

Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether	Structural Classification Monophenols Source classification Phenols Acanthopanax senticosus (Rupr. et Maxim.) Harms Plants Araliaceae	Others
Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether is a DGAT1 inhibitor with an IC₅₀ of 92.7 μM and can be extracted from Eleutherococcus senticosus. Guaiacylglycerol-8-O-4'-(sinapyl alcohol) ether can be utilized in research related to type II diabetes and obesity .

(Rac)-Phytosphingosine (Rac)-4-Hydroxysphinganine	Structural Classification Natural Products other families Source classification Plants	Others
(Rac)-Phytosphingosine ((Rac)-4-Hydroxysphinganine) is the racemate of Phytosphingosine (HY-W011303). Phytosphingosine is a phospholipid with anti-inflammatory, antibacterial, and anti-cancer activities, which can induce apoptosis. Phytosphingosine is an immune regulator and can be used in the study of inflammatory skin diseases. Phytosphingosine is also an activator of GPR120 with an IC₅₀ value of 33.4 μM and can be used in the study of type II diabetes .

D-Tagatose (Standard)	Structural Classification Microorganisms Source classification Endogenous metabolite Saccharides Monosaccharides	Endogenous Metabolite
D-Tagatose (Standard) is the analytical standard of D-Tagatose. This product is intended for research and analytical applications. D-Tagatose (D-(-)-Tagatose) is a rare monosaccharide found in nature with prebiotic characteristics. D-Tagatose is as a substitute for sucrose and a low-calorie sweetener in foodstuffs such as gum, fruit juice, and beverages. D-Tagatose is also a potential antidiabetic agent for the research of type II diabetes and a prebiotic to help elevate beneficial bacteria in the colon, prevent colon cancer, and lower cholesterol .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks